Oral IRAK-4 inhibitor CA-4948 is blood-brain barrier penetrant and has single-agent activity against CNS lymphoma and melanoma brain metastases.
Christina A von RoemelingBently P DoonanKelena KlippelDaniel C SchultzLan Hoang-MinhVrunda TrivediChenglong LiRylynn RussellSiva Rama Raju KanumuriAbhisheak SharmaHan W TunDuane A MitchellPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
IRAK-4 is an attractive target in PCNSL and MBM. The inhibition of IRAK-4 with CA-4948 downregulates the expression of important transcription factors involved in tumor growth and proliferation. CA-4948 is currently being investigated in clinical trials for relapsed and refractory lymphoma and warrants further translation into PCNSL and MBM.
Keyphrases
- blood brain barrier
- diffuse large b cell lymphoma
- brain metastases
- clinical trial
- small cell lung cancer
- transcription factor
- cerebral ischemia
- poor prognosis
- protein kinase
- acute lymphoblastic leukemia
- signaling pathway
- multiple myeloma
- hodgkin lymphoma
- randomized controlled trial
- atomic force microscopy
- open label
- mass spectrometry
- high speed